Venture Life, Alliance Pharma Extend Contract

Alliance is an international pharmaceutical company specialising in the acquisition and licensing of healthcare products. It has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors. 

Venture Life manufactures a number of products for Alliance and the agreement confirms the extension of these arrangements to December 31, 2025. It also incorporates the manufacture of new products generating additional revenues to the Company of at least €1.6m annually. Subject to regulatory requirements and order timings, this new additional business will likely start at some point during H2 2018. 

Jerry Randall, chief executive officer of Venture Life said, “We’re delighted to announce this contract extension out to 2025. Alliance is one of our more significant customers and this agreement is a testament to the confidence they have in us and our ability to deliver. In addition to the significant additional business Alliance has agreed to place with us, a further positive is that as part of this deal, we have also been given the opportunity to pitch for future new business that Alliance may put out to tender. We are now well positioned as a valued strategic partner to Alliance and our strong relationship will give shareholders confidence in us as we go forward.”

Peter Butterfield, chief executive officer of Alliance Pharma plc said, “We are actively fostering longer term relationships with our key strategic suppliers and are pleased to extend our relationship with Venture Life. Their consistent service and quality excellence will play a pivotal role in delivering growth and unlocking future benefits for both sides.”